18 December 2025
FDA Approves Boehringer Ingelheim's JASCAYD for Progressive Pulmonary Fibrosis
JASCAYD, a PDE4B inhibitor, slows lung function decline in progressive pulmonary fibrosis, offering a new treatment option based on Phase III trial results.